Generic Option for ADHD Approved

The US Food and Drug Administration has recently approved the first generic version of Strattera (atomoxetine) for the treatment of attention-deficit/hyperactivity disorder in adult and pediatric patients.

Atomoxetine was approved in multiple strengths and is taken as an oral capsule.
______________________________________________________________________________________________________________________________________________________________________

RELATED CONTENT
Adherence to a Mediterranean Diet Linked to Lower Risk of ADHD
New Brain Test Aids ADHD Diagnosis
______________________________________________________________________________________________________________________________________________________________________

Common adverse effects associated with atomoxetine in children and adolescents included upset stomach, decreased appetite, nausea or vomiting, dizziness, tiredness, and mood swings.

For adult patients, the most common adverse side effects included constipation, dry mouth, nausea, decreased appetite, sexual side effects, problems passing urine, and dizziness. Other adverse effects associated with atomoxetine included severe liver damage and potential for serious cardiovascular events.

In addition, atomoxetine increases the risk of suicidal ideation in children and adolescents. Health Care providers should monitor patients taking this medication for clinical worsening, suicidality, and unusual changes in behavior, particularly within the first few months of initiation or during dose changes.

—Melissa Weiss

Reference:

FDA approves first generic Strattera for the treatment of ADHD [Press release]. FDA. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm561096.htm. Published May 30, 2017. Accessed May 31, 2017.